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Introduction
The International Diabetes Federation project that the global prevalence of diabetes mellitus is set to rise to approximately 600 million by 2035. 1 Foot ulcers complicating diabetes are burdensome for patients and costly for society. There is a paucity of robust evidence on the prevention and management of diabetic foot ulcers (DFU's) to inform treatment, leading to calls for higher quality research from recently published systematic reviews. 2, 3, 4, 5, 6, 7 As a consequence Jeffcoate et al.
2016 produced a 21-point (TOP) checklist on behalf of the International Working Group on the Diabetic Foot (IWGDF) and the European Wound Management Association (EWMA) both highlighting and addressing the shortcomings of existing appraisal methodologies. This checklist integrates the exigencies of diabetic foot reporting standards into a single disease specific research appraisal tool. 8 TOP summarises details that should be included in study design, conduct, and reporting for publications addressing prevention and management of DFU's. The ultimate goal is of course that the research community will adopt the specified criteria into future reports to improve reporting standards. To date no study has examined the utility or validity of the TOP checklist in assessing the current quality of published work on DFU's.
The aim of this study was to appraise the current quality of the evidence addressing the diagnosis, prognosis and management of peripheral artery disease (PAD) in patients with DFU's using the TOP checklist. The IWGDF has been publishing and updating international guidelines on the prevention and management of foot problems in diabetes since 1999 based upon best available evidence. We decided to use IWGDF guidance as a source of original research to examine the current quality of reporting standards in the diabetic foot ulcer literature.
Methodology
We utilised the 2015 IWGDF guidance on diagnosis, prognosis, and management of PAD in patients with foot ulcers in diabetes to identify studies pertaining to the prevention and management of DFU. 10 Within this document are cited three systematic reviews that summarise the literature, all conforming to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidance. 11 Using the studies cited by (n = 57), Brownrigg et al. 2016 (n = 10) and Brownrigg et al. 2016 (n = 11) we identified a total of 78 original research articles to be assessed in our study. 4, 12, 13 We categorised studies into case series, cross-sectional studies, cohort studies and randomised trials.
We used the TOP scoring system to assess the quality of published work cited within the systematic reviews. Three broad areas of study design, study conduct and outcome reporting were assessed according to this checklist with a maximum score of 11, 6 and 4 respectively. For non-randomised studies it was not possible to score in some domains of the TOP checklist by virtue of the deficiencies in their design. Medians are reported alongside range. The change in score by year of publication was tested using Spearman's rank correlation coefficient, which is a non-parametric measure of rank correlation, and p < 0.05 was considered statistically significant.
Results
The most common study design was case series (n = 54), followed by cohort study (n = 19) and crosssectional study (n = 5). There were no randomised trials.
The overall (total) median score was 8 (3-12) out of 21. The median design total score was 2 (0-4) out of 11.The median conduct total score was 2(1-4) out of 6. The median outcomes total score was 3 (1-4) out of 4.
Over the period of the analysis there was improvement with time in the overall total (Spearman Rho 0.39, p=0.0005), design total (0.35, p =0.0023), outcomes total (0.35, p=0.0002) but not the conduct total (-0.03, p=0.8132) scores. Figure 1 demonstrates however that the improvements for the overall and design total though statistically significant hide the fact that the overall quality of studies remains poor. Table 1 lists and summarises the results for each item in the TOP scoring system. With regards to items addressing study design, only 21% of studies used appropriate definitions for "ulcer", "healing", and all other aspects of the population studied and their outcomes. The quality of reporting for this item did improve over the course of the study (Spearman Rho 0.35, p=0.0015).
Only 17% of studies chose a primary outcome of direct clinical relevance. No studied randomised or blinded the researchers, clinicians or participants. Only one study performed an appropriate sample size calculation. 14 15% of studies documented the primary outcome in 75% or more of participants whilst 5% analysed the results primarily by intention to treat analysis.
The reporting of outcomes was judged to be more robust except that only 51% of studies discussed the important strengths and weaknesses of the study, though this did improve over the course of the analysis (Spearman Rho 0.44, p>0.0001).
Except for the two items already highlighted no other individual item demonstrated a significant improvement over the course of the analysis.
Discussion

Improvement with time
There has been modest improvement with time in the reporting of study design and outcomes, leading to improvements in the overall total TOPS score. The improvements in study design reflect moderate improvements in the use of appropriate definitions for key aspects of the population and outcome as well as for the detail with which studies were described. The improvements in study outcome reporting largely reflect an improvement in the description of study strengths and weaknesses over time. These improvements may reflect the introduction of guidelines for reporting observational studies such as STROBE. 15 It must be emphasised that the reporting for the majority of items listed in TOPS did not improve over time. This probably reflects a failure of authors to accommodate the multifactorial aetiology of foot ulceration in patients with diabetes, nor their multidisciplinary management.
Overall poor quality
Whilst this analysis revealed an improvement over time in the overall calibre of studies addressing the diagnosis, prognostication and revascularisation of patients with diabetes and PAD, the present quality remains poor. This is particularly true for the design and conduct of studies. This is attributable to a number of factors which we discuss here.
Poor quality of design and conduct
Studies to date have failed to address the issue of heterogeneity of patients with DFU's. It is very difficult from the present literature to ascertain the impact of current management strategies as very few studies have used appropriate definitions of ulcer and PAD severity or healing. [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] Future analysis will need to stratify patients by severity and use more robust measures of outcome to improve the external validity of studies.
Interventions as part of PAD management in patients with DFU's are inevitably given in conjunction with other components of care such as ulcer offloading footwear, dressings, antimicrobials and pharmacological regimes. These vital components need to be accounted for in trial design and to be adequately described for external validity and to facilitate critical appraisal of comparative data. A common observation throughout the analysis was that very few authors reported these other components of care. 16, 18, 19, 23, 25, 26, [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] It is common research practise to define primary outcome at the time of study design to reduce the risk of type I error resulting from the statistical testing of many outcomes and type II error by providing the basis for a sample size calculation and an adequately powered study. Primary outcome measures were infrequently documented in the studies examined, compromising the internal validity of and the conclusions which can be gleaned from these reports. 14, 17, 20-22, 34, 43-49 Given that there were no randomised studies included in the analysis, features of this specific trial design (control group, independent randomisation, blinding and control group performance), that account for 19% of the total TOPS checklist as markers of good quality, could not be awarded in any case. The paucity of these hallmarks of trial quality highlight the overall need for RCT's in the DFU literature.
Diagnosis
Non-invasive tests for the detection of PAD among individuals with diabetes help to estimate the risk of amputation, ulceration, wound healing and the presence of cardiovascular disease. Despite this rationale, there is no evidence to support a single non-invasive diagnostic test for PAD detection across the spectrum of patients with diabetes. 4 Diagnostic performance varies according to populations studied and a poor description of these cohorts in the literature limits the applicability of any findings to a particular patient group. 4 Standardized reporting would establish comparative datasets to identify which test(s) can best identify PAD assisting in diagnosis, prognostication and management of diabetic foot complications and cardiovascular risk.
Screening tests for PAD can help to identify patients at higher risk of ulceration and most importantly those at greater risk of amputation when tissue loss is already established. 4 Particularly in this latter group the majority of the literature again fails to stratify patients according to disease severity (neuropathy, ulcer classification etc.) and therefore the differential utility of each test in the various strata is unclear. 42, [50] [51] [52] [53] [54] [55] [56] 
Prognostication
There is a consensus that PAD is associated with poor outcome in DFU, however the exact PAD characteristics which correlate with a poor outcome is unknown. 12 PAD is variable in its distribution and severity with a tendency of diabetic patients to have diffuse and distal disease with a greater prevalence of medial sclerosis and poor collateral formation. We need to address the clinically important questions of whether it is possible to identify specific characteristics of PAD that predict a poor outcome, at which point in the disease natural history is revascularization is needed to prevent a poor outcome, or whether there is a group of patients in whom a poor outcome is likely regardless of revascularization. In the current analysis of prognostic studies only six studies included appropriate definitions for the terms "ulcer", "healing" and all other required aspects of the population and the outcomes. [24] [25] [26] [27] [28] [29] The development of a registry to standardize data collection addressing the poor quality of evidence currently available, would help to determine which demographic, comorbidity, ulcer-related and PAD factors predict failure to heal. Standardisation of data collection and reporting would allow comparisons of practice and outcome across research sites to maximizing precision, whilst accounting for heterogeneity and allowing adjusted for potential confounding factors.
Treatment
Much of the literature focuses on procedure specific (technical success, re-stenosis, target lesion revascularisation) instead of disease specific (wound healing, major amputation) or clinical (amputation free survival) outcome measures. Specifically only 17% of studies defined a primary outcome of direct clinical relevance. Future study designs should address this discrepancy and ensure that appropriately sized studies powered to detect clinically relevant differences are undertaken.
There are no studies addressing the effectiveness of revascularisation versus best medical and wound therapy alone in patients with diabetes related foot ulceration. Whilst it is unlikely such a trial would ever be conducted more robust stratification of patients in observational studies could allow a comparison of successfully and unsuccessfully revascularised patients according to disease severity. Randomised trials comparing the various revascularisation strategies are warranted and it is important that these are conducted on or robust sub-group analysis performed in patients with diabetes.
Limitations
We acknowledge that the creation of the TOPS checklist was based upon expert opinion from IWGDF members. Delphi consensus would have been the gold standard methodology to produce a recognised validated appraisal tool. There is very little robust methodology in the vascular surgery literature that considers validating disease specific appraisal tools and none specifically centred on reporting standards. However, Delphi consensus methodology has been successfully used to develop and adopt a core outcome sets for use in colorectal cancer surgical trials and research and also audit studies in reconstructive breast surgery. 57, 58 We selected the evidence addressing the diagnosis, prognosis and management of PAD in patients DFU's as a surrogate of the overall quality of reporting standards in the DFU literature. We recognise that including all of the IWGDF group's systematic reviews would have comprehensively appraised the entirety of the DFU literature to provide an analysis representative of the other preventative and treatment modalities.
Conclusion
This study appraised the quality of reporting in the literature surrounding the diagnosis, prognosis and management of PAD in patients with DFU's using the TOP checklist. Future work should focus on validating the TOP checklist not only for its use in PAD but also for studies examining prevention of foot ulcers in at-risk patients, footwear and offloading to prevent and heal foot ulcers, diagnosis and management of foot infections in persons with diabetes as well as interventions to enhance healing of chronic DFU's. The TOP checklist focuses on reporting standards and incorporates aspects on outcome reporting as markers of good quality. Ultimately, the DFU research community should aspire to achieve a core outcome dataset as described by our colleagues in colorectal and breast reconstruction surgery. Only then would we be able to truly compare results from individual studies having diminished the marked heterogeneity in reporting observed in this analysis. The ultimate aim is to be able to stratify the DFU patient population in such a way as to be able to select and target treatments to the most appropriate subgroup. 
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